Accolade, Inc. (NASDAQ:ACCD) Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC lifted its stake in shares of Accolade, Inc. (NASDAQ:ACCD) by 36.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 40,498 shares of the company’s stock after acquiring an additional 10,749 shares during the period. SG Americas Securities LLC’s holdings in Accolade were worth $139,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the company. Centiva Capital LP lifted its position in Accolade by 5.8% during the third quarter. Centiva Capital LP now owns 59,660 shares of the company’s stock valued at $230,000 after buying an additional 3,264 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Accolade by 13.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 29,160 shares of the company’s stock worth $104,000 after purchasing an additional 3,416 shares during the last quarter. Mission Creek Capital Partners Inc. bought a new stake in shares of Accolade in the 3rd quarter valued at approximately $38,000. Inspire Investing LLC boosted its holdings in shares of Accolade by 11.1% in the 3rd quarter. Inspire Investing LLC now owns 106,679 shares of the company’s stock valued at $411,000 after buying an additional 10,658 shares during the period. Finally, Pallas Capital Advisors LLC acquired a new stake in Accolade during the fourth quarter worth about $38,000. Hedge funds and other institutional investors own 84.99% of the company’s stock.

Insider Buying and Selling at Accolade

In other news, CEO Rajeev Singh sold 13,357 shares of the stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $3.60, for a total value of $48,085.20. Following the completion of the transaction, the chief executive officer now owns 814,316 shares of the company’s stock, valued at approximately $2,931,537.60. This represents a 1.61 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 40,145 shares of company stock valued at $157,917 in the last ninety days. 8.20% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ACCD. Needham & Company LLC reiterated a “hold” rating on shares of Accolade in a research report on Wednesday, January 8th. William Blair cut shares of Accolade from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 8th. Leerink Partnrs lowered shares of Accolade from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 8th. Canaccord Genuity Group reissued a “hold” rating on shares of Accolade in a research note on Wednesday, January 8th. Finally, Leerink Partners restated a “market perform” rating on shares of Accolade in a research note on Wednesday, January 8th. Twelve equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $7.55.

Accolade Stock Up 0.1 %

Accolade stock opened at $6.89 on Tuesday. The company has a 50 day moving average of $5.05 and a 200-day moving average of $4.25. Accolade, Inc. has a twelve month low of $3.08 and a twelve month high of $13.93. The stock has a market capitalization of $562.16 million, a PE ratio of -3.06 and a beta of 2.20. The company has a quick ratio of 2.63, a current ratio of 2.63 and a debt-to-equity ratio of 0.67.

Accolade (NASDAQ:ACCD) last announced its quarterly earnings results on Friday, January 10th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.01. Accolade had a negative net margin of 40.36% and a negative return on equity of 20.74%. On average, equities research analysts anticipate that Accolade, Inc. will post -1.2 EPS for the current fiscal year.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.